<DOC>
	<DOC>NCT02433587</DOC>
	<brief_summary>The primary objective of the trial is to evaluate short versus long duration dual antiplatelet therapy in patients undergoing lower extremity endovascular revascularization.</brief_summary>
	<brief_title>Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1. Provide signed informed consent before initiation of any study related procedures 2. Be at least 18 years of age 3. Successful percutaneous lower extremity (iliac and infrainguinal) endovascular revascularization (percutaneous transluminal angioplasty, and /or stent). 4. At least 1 vessel runoff in segment distal to the intervention 5. Rutherford Classification 25 that is unresponsive to medical therapy 1. Acute limb ischemia 2. Procedure includes device deployment that has specific FDA regulations for anticoagulation/antiplatelet medication regimen. 3. Patient undergoing atherectomy procedure 4. Intervention includes deployment of drug eluted stent 5. Critical limb ischemia (Rutherford Classification 6) 6. Thrombocytopenia: Platelet count &lt;50k 7. Liver disease (ChildsPugh B or C) 8. Existing need for on going clopidogrel therapy 9. Proton Pump Inhibitor Use (If unable to be switched) 10. Need for therapeutic anticoagulation 11. Known hypercoagulable disorder 12. Allergy or contraindication to aspirin or clopidogrel 13. Pregnancy 14. Patients enrolled in another investigational drug or device study within the past 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>